Screening, domestication and identification of intestinal uric acid degrading bacteria in low uric acid population_Journal of Biomedical Engineering

Authors：

TIAN Tingting ¹ , CHEN Wujin ² , LIANG Meiting ¹ , Mayina Kahaer ³ , LI Rui ³ ,  SUN Yuping ^3,4

1. Basic Medical College, Xinjiang Medical University, Urumqi 830000, P. R. China;
2. Morphological Center, Basic Medical College, Xinjiang Medical University, Urumqi 830000, P. R. China;
3. Department of Microbiology, Basic Medical College, Xinjiang Medical University, Urumqi 830000, P. R. China;
4. Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjiang Medical University, Urumqi 830000, P. R. China;

Corresponding?author：

SUN Yuping, Email: 544481723@qq.com

Keywords：

Low uric acid population; Uric acid degrading bacteria; Screen; Domestication; Uric acid degradation rate

DOI：

10.7507/1001-5515.202111028

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

As the largest ecosystem of human body, intestinal microorganisms participate in the synthesis and metabolism of uric acid. Developing and utilizing intestinal bacteria to degrade uric acid might provide new ideas for the treatment of hyperuricemia. The fecal samples of people with low uric acid were inoculated into uric acid selective medium with the concentration of 1.5 mmol/L for preliminary screening, and the initially screened strains that may have degradation ability were domesticated by concentration gradient method, and the strains with high uric acid degradation rate were identified by 16S rRNA sequencing method. A strain of high-efficiency uric acid degrading bacteria was screened and domesticated from the feces of people with low uric acid. The degradation rate of uric acid could reach 50.2%. It was identified as Escherichia coli. The isolation and domestication of high efficient uric acid degrading strains can not only provide scientific basis for the study of the mechanism of intestinal microbial degradation of uric acid, but also reserve biological strains for the treatment of hyperuricemia and gout in the future.

Citation： TIAN Tingting, CHEN Wujin, LIANG Meiting, Mayina Kahaer, LI Rui, SUN Yuping. Screening, domestication and identification of intestinal uric acid degrading bacteria in low uric acid population. Journal of Biomedical Engineering, 2022, 39(4): 792-797. doi: 10.7507/1001-5515.202111028 Copy

1.	李豐琴, 葉志斌. 高尿酸血癥與糖尿病及其并發癥研究進展. 中國實用內科雜志, 2017, 37(6): 569-572.
2.	Sandra S, Lesmana C R A, Purnamasari D, et al. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: lesson learnt from tertiary referral center. Diabetes Metab Syndr, 2019, 13(1): 424-428.
3.	Su Pu, Hong Liu, Zhao Yifan, et al. Relationship between hyperuricemia and cardiovascular disease risk factors in a Chinese population: a cross-sectional study. Med Sci Monit, 2015, 12(21): 2707-2717.
4.	何向陽, 劉崢, 徐英, 等. 肥胖與四種常見慢性病的相關性分析. 預防醫學, 2020, 32(7): 692-697.
5.	王天宇, 竇倩, 郭子坤, 等. 1947例體檢人群高血壓與高血糖和高尿酸血癥及血脂異常關系分析. 社區醫學雜志, 2020, 18(22): 1509-1511.
6.	Lloyd-price J, Abu-ali G, Huttenhower C. The healthy human microbiome. Genome Med, 2016, 8(1): 51.
7.	Guo Zhuang, Zhang Jiachao, Wang Zhanli, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep, 2016, 6: 20602.
8.	紀澤敏. 基于臨床病例篩選高尿酸血癥相關的腸道菌群. 北京: 中央民族大學, 2020.
9.	Ning Yaogui, Yang Guomei, Chen Yangchun, et al. Characteristics of the urinary microbiome from patients with gout: a prospective study. Front Endocrinol (Lausanne), 2020, 11: 272.
10.	Yu Yiran, Liu Qiuping, Li Haichang, et al. Alterations of the gut microbiome associated with the treatment of hyperuricemia in male rats. Fro Mic, 2018, 9: 2233.
11.	任科雨, 勇春明, 金延春, 等. 青島地區高尿酸血癥患者的腸道菌群分析. 中國醫師雜志, 2014, 16(12): 1649-1651.
12.	孫玉萍, 陳鄔錦, 梁美婷,等. 用于篩選腸道降解尿酸菌株的高尿酸培養基及其制備方法: CN112831448A. 2021-05-25.
13.	Ma Quantao, Li Yaqi, Li Pengfei, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother, 2019, 117: 109138.
14.	董文學, 蔣雅瓊, 馬利鋒, 等. 腸道菌群對尿酸代謝的影響. 胃腸病學和肝病學雜志, 2021, 30(1): 55-59.
15.	Liu Hong, Zhang Xiaomin, Wang Yanli, et al. Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol, 2014, 27: 653-658.
16.	Browne H P, Forster S C, Anonye B O, et al. Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. Nature, 2016, 533(7604): 543-546.
17.	Yu Yiran, Liu Qiuping, Li Haichang, et al. Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats. Front Endocrinol, 2018, 9: 1-10.
18.	Schultz A C, Nygaard P, Saxild H H. Functional analysis of 14 genes that constitute the purine catabolic pathway in Bacillus subtilis and evidence for a novel regulon controlled by the PucR transcription activator. J Bacteriol, 2001, 183(11): 3293-3302.
19.	Lee Y, Lee D H, Kho C W, et al. Transthyretin-related proteins function to facilitate the hydrolysis of 5-hydroxyisourate, the end product of the uricase reaction. FEBS Lett, 2005, 579: 4769-4774.
20.	Guzmán K, Badia J, Giménez R, et al. Transcriptional regulation of the gene cluster encoding allantoinase and guanine deaminase in Klebsiella pneumoniae. J Bacteriol, 2011, 193(9): 2197-2207.
21.	Iwadate Y, Kato J I. Identification of a formate-dependent uric acid degradation pathway in Escherichia coli. J Bacteriol, 2019, 201(11): e00573-18.
22.	常宇驍. 人類腸道微生物培養組優化及腸道菌庫構建與應用. 北京: 軍事科學院, 2020.
23.	Papakostas K, Frillingos S. Substrate selectivity of YgfU, a uric acid transporter from Escherichia coli. J Biol Chem, 2012, 287(19): 15684-15695.
24.	王智. 抗高尿酸血癥藥物的研究進展. 中國城鄉企業衛生, 2019, 34(5): 34-36.

1. 李豐琴, 葉志斌. 高尿酸血癥與糖尿病及其并發癥研究進展. 中國實用內科雜志, 2017, 37(6): 569-572.
2. Sandra S, Lesmana C R A, Purnamasari D, et al. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: lesson learnt from tertiary referral center. Diabetes Metab Syndr, 2019, 13(1): 424-428.
3. Su Pu, Hong Liu, Zhao Yifan, et al. Relationship between hyperuricemia and cardiovascular disease risk factors in a Chinese population: a cross-sectional study. Med Sci Monit, 2015, 12(21): 2707-2717.
4. 何向陽, 劉崢, 徐英, 等. 肥胖與四種常見慢性病的相關性分析. 預防醫學, 2020, 32(7): 692-697.
5. 王天宇, 竇倩, 郭子坤, 等. 1947例體檢人群高血壓與高血糖和高尿酸血癥及血脂異常關系分析. 社區醫學雜志, 2020, 18(22): 1509-1511.
6. Lloyd-price J, Abu-ali G, Huttenhower C. The healthy human microbiome. Genome Med, 2016, 8(1): 51.
7. Guo Zhuang, Zhang Jiachao, Wang Zhanli, et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep, 2016, 6: 20602.
8. 紀澤敏. 基于臨床病例篩選高尿酸血癥相關的腸道菌群. 北京: 中央民族大學, 2020.
9. Ning Yaogui, Yang Guomei, Chen Yangchun, et al. Characteristics of the urinary microbiome from patients with gout: a prospective study. Front Endocrinol (Lausanne), 2020, 11: 272.
10. Yu Yiran, Liu Qiuping, Li Haichang, et al. Alterations of the gut microbiome associated with the treatment of hyperuricemia in male rats. Fro Mic, 2018, 9: 2233.
11. 任科雨, 勇春明, 金延春, 等. 青島地區高尿酸血癥患者的腸道菌群分析. 中國醫師雜志, 2014, 16(12): 1649-1651.
12. 孫玉萍, 陳鄔錦, 梁美婷,等. 用于篩選腸道降解尿酸菌株的高尿酸培養基及其制備方法: CN112831448A. 2021-05-25.
13. Ma Quantao, Li Yaqi, Li Pengfei, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother, 2019, 117: 109138.
14. 董文學, 蔣雅瓊, 馬利鋒, 等. 腸道菌群對尿酸代謝的影響. 胃腸病學和肝病學雜志, 2021, 30(1): 55-59.
15. Liu Hong, Zhang Xiaomin, Wang Yanli, et al. Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol, 2014, 27: 653-658.
16. Browne H P, Forster S C, Anonye B O, et al. Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. Nature, 2016, 533(7604): 543-546.
17. Yu Yiran, Liu Qiuping, Li Haichang, et al. Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats. Front Endocrinol, 2018, 9: 1-10.
18. Schultz A C, Nygaard P, Saxild H H. Functional analysis of 14 genes that constitute the purine catabolic pathway in Bacillus subtilis and evidence for a novel regulon controlled by the PucR transcription activator. J Bacteriol, 2001, 183(11): 3293-3302.
19. Lee Y, Lee D H, Kho C W, et al. Transthyretin-related proteins function to facilitate the hydrolysis of 5-hydroxyisourate, the end product of the uricase reaction. FEBS Lett, 2005, 579: 4769-4774.
20. Guzmán K, Badia J, Giménez R, et al. Transcriptional regulation of the gene cluster encoding allantoinase and guanine deaminase in Klebsiella pneumoniae. J Bacteriol, 2011, 193(9): 2197-2207.
21. Iwadate Y, Kato J I. Identification of a formate-dependent uric acid degradation pathway in Escherichia coli. J Bacteriol, 2019, 201(11): e00573-18.
22. 常宇驍. 人類腸道微生物培養組優化及腸道菌庫構建與應用. 北京: 軍事科學院, 2020.
23. Papakostas K, Frillingos S. Substrate selectivity of YgfU, a uric acid transporter from Escherichia coli. J Biol Chem, 2012, 287(19): 15684-15695.
24. 王智. 抗高尿酸血癥藥物的研究進展. 中國城鄉企業衛生, 2019, 34(5): 34-36.

Journal of Biomedical Engineering

Screening, domestication and identification of intestinal uric acid degrading bacteria in low uric acid population

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content